key: cord-0258481-gdnfwe62
authors: Amcheslavsky, Alla; Wallace, Aaron; Ejemel, Monir; Li, Qi; McMahon, Conor; Stoppato, Matteo; Giuntini, Serena; Schiller, Zachary A.; Pondish, Jessica; Toomey, Jacqueline R.; Schneider, Ryan; Meisinger, Jordan; Heukers, Raimond; Kruse, Andrew C.; Barry, Elieen M.; Pierce, Brian; Klempner, Mark S.; Cavacini, Lisa A.; Wang, Yang
title: Oral administration of a single anti-CfaE nanobody provides broadly cross-protective immunity against major pathogenic Enterotoxigenic Escherichia coli strains
date: 2020-06-17
journal: bioRxiv
DOI: 10.1101/2020.06.16.155465
sha: 3405f44c2d3145ac1f298f65d32e72ce790f93db
doc_id: 258481
cord_uid: gdnfwe62

Enterotoxigenic Escherichia coli (ETEC) is estimated to cause approximately 380,000 deaths annually during sporadic or epidemic outbreaks worldwide. There is currently no vaccine licensed to prevent ETEC. Development of prophylaxis against ETEC is challenging due to the vast heterogeneity of the ETEC strains. The discovery of nanobodies has emerged as a successful new biologics in treating mucosal infectious disease as nanobodies can recognize conserved epitopes on hypervariable pathogens. In this study, we performed large screens using immunized llamas and a naïve nanobody yeast display library against adhesins of colonization factors. Cross-protective nanobodies were selected with in vitro activities inhibiting mannose-resistant hemagglutination (MRHA) against all eleven major pathogenic ETEC strains. Oral administration of nanobodies led to significant reduction of bacterial colonization in animals challenged with multiple ETEC strains. Structural analysis revealed novel conserved epitopes as critical structural features for pan-ETEC vaccine design. Two of the lead nanobodies, 2R215 and 1D7, were further engineered as trimer or fused with human IgA Fc-fragments as fusionbodies. Oral administration of the trimers or fusionbodies protected mice from infection at a much lower dose compared to the monomeric format. Importantly, fusionbodies prevented infection as a pre-treatment when administrated 2 hours before ETEC challenge to the animals. Together, our study provides the first proof of concept that oral administration of a single nanobody could confer broad protection against major pathogenic ETEC strains. Technological advances in large-scale manufacturing of biological proteins in plants and microorganisms will make nanobody-based immunotherapy a potent and cost-effective prophylaxis or treatment for ETEC.

ETEC is a non-invasive pathogen that mediates small intestine adherence through bacterial 53 surface structures known as colonization factors (CFs) . Once bound to the small intestine, the 54 bacteria produce toxins causing a net flow of water from enterocytes, leading to watery diarrhea. 55 Development of an effective vaccine against ETEC bacterial attachment and colonization has 56 long been considered as a promising approach against ETEC diarrhea. CFA/I is one of the most 57 prevalent CFs and is composed of CfaE, the tip minor adhesin subunit, and a homopolymeric 58 structural subunit, CfaB. In human clinical trials, oral administration of anti-CfaE bovine IgG 59 provided protection against virulent ETEC challenge in over 60% of the test group, suggesting 60 that an adhesin-based vaccine could be effective to elicit endogenous production of protective 61 antibodies (4). Recent studies in our laboratories demonstrated that when administered orally to 62 mice and non-human primates, anti-CfaE human monoclonal antibodies inhibited bacterial 63 colonization in the small intestine and protected animals from diarrhea associated with ETEC 64 infection (5).

ETEC strains are antigenically diverse with over 25 types of CFs having been identified (6-9) . 67 CFA/I represent the archetype of class 5 fimbriae, the largest class of human specific CFs that 68 causes a majority of moderate to severe ETEC diarrheal cases (7, 9, 10) . Class 5 fimbriae 69 includes three sub-classes, 5a (CFA/I, CS4, CS14), 5b (CS1, CS17, CS19, PCF071), and 5c 70 (CS2). Other non-class 5 fimbriae have also been implicated in endemic and traveler diarrheal 71 diseases including helical CS5, fibrillary CS3, CS21 and non-fimbrial CS6 adhesins (11). As 72 such, development of a broadly protective vaccine against all major pathogenic ETEC strains 73 remains one of the most important challenges in vaccine design (12, 13) . In theory, a cross-74 protective vaccine could be generated with a combination of intact CFs (14) . However, such 75 strategies could lead to unexpected instability or safety concerns and high costs for The discovery of camelid heavy-chain variable domains (VHHs or nanobodies) has produced a 80 new application for antibody-derived biologics (15). Nanobodies consist of a highly stable and 81 soluble single antigen-binding variable region (15 kDa), since they are derived from heavy chain 82 only antibodies with no associated light chains (16). Unlike conventional antibodies, nanobodies 83 can access distinct antigenic sites (e.g., enzyme active sites, recessed regions of viral 84 glycoproteins) due to smaller paratope diameters and a longer complementarity-determining 85 region 3 (CDR3) to form finger-like extensions (15, 17 101 To generate nanobodies with broad cross-reactivity against ETEC adhesins, two male llama were 102 subcutaneously immunized with N-terminal fragments of eight class 5 ETEC adhesins ( Figure   103 1A). Serum response to adhesins was measured by ELISA and PBMC were isolated from llama 104 to generate phage-displayed libraries of size around 10 8 as previously described (26). Libraries 105 were initially used for panning on immobilized colonization factor antigens CS1 and CS2, 106 because of their relatively low sequence homology. Output from those pannings were used for a 107 subsequent panning round on CfaE. Periplasmic extracts were prepared and tested for binding to 108 all 8 adhesin antigens in ELISA. Cross-reactive clones were sent for sequence determination and 109 further characterization. From these selections, 26 candidate nanobodies were selected. 128 To test the breadth of cross-reactivity, selected llama-and yeast-derived nanobodies were 129 sequenced, cloned in pET-26b vector, expressed in E.coli, and examined by ELISA for binding 130 to eight class 5 adhesins. Two yeast-derived clones (2R215 and 2R23) and two llama-derived 131 clones (1D7 and 1H4) were selected based on their broad reactivity against multiple adhesins 132 (Figure 2A-D) . The four lead nanobodies were then tested for inhibition of mannose resistant 133 hemagglutination (MRHA) against an ETEC strain expressing CFA/I (H10407), the most 134 prevalent class 5 adhesin. All nanobodies showed maximal inhibitory concentration (IC100) in the 135 micromolar concentration range (1.9 to 3.7µM) ( Figure 2E ). We next examined if these 136 nanobodies had activity against ETEC strains expressing 7 other class 5 adhesins in MRHA 137 assay. Consistent with ELISA binding data, the four nanobodies were cross-protective against all 138 eight strains with an IC100 activity ranging from 0.4125 to 13.2 µM ( Table 1) .We next examined 139 the MRHA activity of nanobodies against ETEC strains expressing other pathogenic fimbrial and 140 non-fimbrial adhesins including helical CS5, fibrillary CS3, and non-fimbrial CS6 adhesins, as 141 well as another common diarrhea causing adhesin CS21. Surprisingly, four nanobodies showed 142 broad protection against all tested strains with an IC100 ranging from 0.2063 to 6.6 µM ( Table 1) .

To elucidate the interaction between anti-ETEC nanobody and adhesin at the molecular level, we Based on docking results, individual CfaE residues within or adjacent to the putative receptor 153 binding pocket formed by three arginine residues (R67, R181 and R182) were selected for 154 mutagenesis to alanines and tested by ELISA for nanobody binding (Figure 3E-H) . ELISA 155 results showed that mutating Y65, R67, E161, D184, R181, R182, and Y183 to alanine affected 156 the binding of nanobodies to CfaE suggesting that these residues are involved in the binding interactions. This is in line with findings by Baker who demonstrated R181 of CfaE as crucial for 158 ETEC binding in a human in vitro organ culture (30). In addition to the residues near the putative 159 receptor domain, we identified several other highly conserved residues such as S65, L64, Y58, 160 L110, Y156 and C143 that are required for interaction between nanobodies and adhesin.

Interestingly, sequence alignment revealed that these residues are highly conserved among at 162 least eight class 5 adhesins (31), which is consistent with our observation that these nanobody are 163 broadly cross protective against multiple ETEC strains.

The lead nanobodies were further evaluated in a mouse model of ETEC colonization as 167 described previously (29) ( Figure 4A ). Groups of five DBA/2 mice were given a mixture of 168 bacteria and anti-CfaE nanobodies by oral gavage. All nanobodies were tested at 100 mg/kg, 169 except for 2R23, which was tested at 50mg/kg due to the low production yield. Twenty four (Figure 7C, D) . Furthermore, the 1D7 228 VHH-IgA1 fusionbody retained activity when the pre-treatment time was extended to 2 hours. A 229 1.7 log reduction in total CFUs was observed in 1D7 VHH-IgA1 treated animals as compared to 230 the group treated with irrelevant control (P<0.0001) (Figure 7E) . We also compared the activity 

The initial screening was performed against CS1and CS2, followed by a second round of 510 screening against the CfaE antigen. Phages were eluted by unspecific and competitive elutions.

Eluted phage were used to infect exponentially growing E. coli TG1 that were plated on Luria 512 broth (LB) agar plates containing 2% (w/v) glucose and 100 µg/ml ampicillin. In addition, eluted 513 phages were serially diluted, infected in TG1 and 5 µl spots of these infections were plated to 514 allow estimating how many phages were eluted. Periplasmic extracts were prepared according to 515 standard protocols involving overnight production in 2YT medium and induction with IPTG.

Extracts were tested for binding to all 8 Cfa antigens in ELISA. Based on HinfI digestion pattern, 517 amino acid sequences and cross-reactive binding to Cfa antigens, unique candidate genes were 518 selected for further characterization. 

The growth conditions are the same as H10407. Nanobodies were multimerized to dimeric or trimeric forms with (G4S) linkers. The dimeric 568 forms were generated using 6X (G4S) linker to connect two monomeric VHHs in tandem N 569 terminus to C terminus orientation. Trimers were generated using two 3X (G4S) linkers between 570 monomeric nanobody units. The multimers were cloned into pET-26b vector adding a C-571 terminal 6xHis tag. Nanobodies were purified from the periplasmic fraction by Ni-NTA 572 chromatography (Gold Biotechnology) and dialyzed against PBS to remove imidazole.

To generate VHH-IgA fusionbodies, monomeric nanbody sequences were cloned into a pcDNA solution until an OD600 of 1 was reached for the assay. Other ETEC strains except #400599 599 (CS14) were cultured in ETEC medium containing 1% Casamino Acids (Sigma) and 0.15%

Fisher Bioreagents) plus 0.005% MgSO4 (Sigma) and 0.0005% MnCl2

5 mg/ml of Deferoxamine (Sigma Aldrich). CS14-expressing strain (#400599) was 602 cultured on 2% agar containing 1% Casamino Acids (Sigma) and 0.15% yeast extract

CFA agar plates) 604 overnight at 37°C plates. Bacteria was resuspended in 1x PBS and dilutions were used to 605 determine the concentration needed to inhibit hemagglutination

In 609 a U-bottom 96-well plate (Nunc Thermo Scientific), 100 µl of nanobody was added in duplicate 610 to the top row and diluted 1:2 down the plate in a 0.15 M saline solution. Fifty microliters of 611 appropriately diluted ETEC was added to each well together with 50 µl of a 0.1 MD-mannose 612 solution (Sigma). The plate was incubated for 10 min at room temperature. After incubation, 50 613 µl of blood solution was added to the plate and mixed well (200 µl final volume). Plates were 614 allowed to sit stagnant at 4°C for 2 h. Hemagglutination was then observed without the aid of 615 magnification. The absence of a pellet of erythrocytes at the bottom of the well is indicative of 616 positive hemagglutination

Caco-2 adhesion assay

Caco-2 cells seeded at 1x10 4 cells/ml were grown in 96-well tissue culture plates containing 620

Dulbecco's modified Eagle's medium (DMEM), at 37°C in 5% CO2 statically. H10407 strain of 621 ETEC was grown overnight at 37°C in ETEC medium containing 1% Casamino Acids

The next day, bacteria were resuspended in PBS and diluted until an OD600 nm of 0.4 624 was reached. Antibody dilutions were set up in a deep well plate. Antibody dilutions and bacteria 625 were combined at a 1:10 ratio and allowed to shake at 300 rpm

Caco-2 cells were washed and incubated in antibiotic free DMEM containing 500

After incubation, 0.035 ml of the mixture of antibody and bacteria was 628 added to each well containing Caco-2 cells. The cells were then incubated statically for

The cells were then washed four times with 1 ml PBS to remove non adherent ETEC cells 630 and intensity of luciferase signal was determined

One hour prior to bacterial administration, mice received cimetidine 636 (50 mg/kg) intraperitoneally to reduce the effect of stomach acid on ETEC. A total of 1x10 7 CFU 637 of ETEC strains diluted in PBS were incubated with 100 mg/kg of monomeric anti-CfaE 638 nanobody or an irrelevant nanobody 1 h prior to challenge. In pre-mix model, bacteria and 639 nanobody were mixed and administered in 200 µl volume by oral gavage using 20-gauge bulb-640 tip feeding needles. In pre-treatment model, mice were pre-treated with nanobody in 200 µl 641 volume in PBS via oral gavage. One or two hours later, bacteria was administered in 100 µl PBS 642 by oral gavage. The mice were allowed to survive for 24 h. At 12 h before euthanasia, food was 643 withdrawn. Following isolation of the small intestine, two segments of ileum (3 cm each), 644 beginning within 0.5 cm of the ileocecal junction and extending proximally 6 cm, were removed 645 and placed in 1 ml sterile PBS (40)

A total of 17 amino acids predicted by the software to be involved in the 652 interaction between anti-CfaE nanobodies and the N-terminal portion of CfaE were individually 653 by Genscript. The genes were cloned into pMAL-C5x vector, and the resulting 17 constructs 654 were transformed, expressed, and purified as described above

Statistical calculations were performed using the software Prism version 7.03

Comparisons between the hemagglutination or Caco-2 titers of 661 respective antibodies were performed using one-way analysis of variance

Bonferroni correction for post hoc multiple comparisons

Immunizations of llamas and library constructions were performed as described previously (26) .

Briefly, two male llamas were immunized with antigen cocktails that included eight class 5 499 colonization factors (300ug each antigen, 2400ug total for each animal). The first cocktail 500 consisted of CS2, CS4, CS14, CfaE and the second cocktail consisted of CS19, CS17, CS1, and 501 PCF071. The two antigen cocktails were injected to each animal weekly for six weeks and 150 502 ml blood was collected for isolation of RNA from the peripheral blood lymphocytes after the last 503 immunization on the 7 th week. Good immune response was observed in both animals against all 504 antigens. RNA isolation and library constructions were performed by amplifying nanobody 505 genes and ligating into a phagemid vector. Two phage display libraries were generated with a 506 size of approximately 5x10 8 transformed E. coli TG1 bacteria and a correct insert ration of 507 ~100%. Selection of target-binding nanobodies was performed by phage-display selections